Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.
Wee EG. et al, (2019), Molecular therapy. Methods & clinical development, 14, 148 - 160
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
Moyo N. et al, (2019), Molecular Therapy - Methods & Clinical Development, 12, 32 - 46
Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.
Rahim MN. et al, (2019), PLoS pathogens, 15
Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.
Kilpeläinen A. et al, (2019), Frontiers in immunology, 10
Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1
Borthwick NJ. et al, (2018), PLOS ONE, 13, e0197299 - e0197299
HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
Capucci S. et al, (2017), PLOS ONE, 12, e0181886 - e0181886
Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
Moyo N. et al, (2017), PLOS ONE, 12, e0181382 - e0181382
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
Wee EG. et al, (2017), Molecular Therapy, 25, 494 - 503
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection
Ondondo B. et al, (2016), Molecular Therapy, 24, 832 - 842
APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon
Armitage AE. et al, (2012), PLoS Genetics, 8, e1002550 - e1002550
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
Tenzer S. et al, (2009), Nature Immunology, 10, 636 - 646
P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
Tenzer S. et al, (2009), Retrovirology, 6, P252 - P252
Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants
Slyker JA. et al, (2005), Vaccine, 23, 4711 - 4719
A Rab-E GTPase Mutant Acts Downstream of the Rab-D Subclass in Biosynthetic Membrane Traffic to the Plasma Membrane in Tobacco Leaf Epidermis
Zheng H. et al, (2005), The Plant Cell, 17, 2020 - 2036
Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa
Nkolola JP. et al, (2004), Gene Therapy, 11, 1068 - 1080
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans
Mwau M. et al, (2004), Journal of General Virology, 85, 911 - 919
Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine
Hanke T. et al, (2003), Journal of General Virology, 84, 361 - 368
Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost
Vinner L. et al, (2003), Journal of General Virology, 84, 203 - 213